成都先導(688222.SH):減持數過半 騰瀾溪生物累計減持1.86%股份
格隆匯10月21日丨成都先導(688222.SH)公佈,公司於2021年10月20日收到股東騰瀾溪生物關於減持股份數量過半的吿知函,騰瀾溪生物於2021年8月24日至2021年10月20日期間通過集中競價交易方式累計減持其所持有的公司股份2,339,978股,佔公司總股本比例為0.58%,2021年10月15日至2021年10月20日期間通過大宗交易方式累計減持其所持有的公司股份5,092,909股,佔公司總股本比例為1.27%。上述減持合計743.29萬股,減持比例達1.86%。
截至2021年10月20日,本次減持計劃數量過半,減持計劃尚未實施完畢。本次權益變動後,騰瀾溪生物持有公司股份14,540,984股,佔公司總股本的3.63%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.